Table of Contents
Executive Summary — 6
SWOT
Analysis — 8
US Pharmaceuticals And Healthcare Industry
SWOT — 8
United States Political
SWOT — 9
United States Economic
SWOT — 9
United States Business Environment
SWOT — 10
Pharmaceutical Business Environment
Ratings — 11
Table: Regional Pharma Business Environment
Ratings — 11
Limits to Potential
Returns — 12
Risks to Realisation of
Returns — 12
US - Market Summary — 13
Regulatory Regime — 14
Pharmaceutical
Advertising — 15
Table: Examples Of Off-Label Drug
Use — 17
Recent Regulatory
Developments — 18
International Regulatory
Collaboration — 21
Biosimilars — 22
Intellectual Property Developments — 23
Pricing and
Reimbursement Environment — 24
Price
Rises — 25
Part D — 27
Other
Reimbursement Issues — 29
Industry
Developments — 30
Epidemiology — 30
Table: Vaccine-Preventable Diseases — 31
Healthcare
Sector — 32
Universal Healthcare — 34
Health Insurance — 35
Healthcare
Expenditure — 36
E-Health — 37
Pharmaceutical Industry — 38
Drug Distribution
Sector — 42
Table: Channel Distribution By US Sales
(US$bn) — 43
Table: Channel Distribution By US Dispensed
Prescription (mn) — 43
Pharmacy Retail
Sector — 44
Table: Leading 10 Products By US Dispensed
Prescriptions (mn) — 45
Cross-Border Pharmacy
Retail — 46
Research and Development
Sector — 47
Clinical Trials
Sector — 48
Biotechnology Sector — 49
Table: Biotechnology Medicines Under Development,
2006 — 49
Medical Device Market — 50
Medical Device Manufacturing — 51
Industry Forecast
Scenario — 54
Overall Market
Forecast — 54
Table: US - Pharmaceuticals And Healthcare
Sector, Historical Data and Forecasts — 55
Key Growth
Factors – Industry — 56
Key Growth Factors –
Industry — 56
Table: US - Healthcare Sector Indicators,
Historical Data And Forecasts — 57
Macroeconomic Forecast
Scenario — 58
Economic Activity — 58
Table: United States - Economic Activity — 61
Prescription
Market Forecast — 62
Table: US – Prescription Market
Indicators, Historical Data And Forecasts (US$mn unless otherwise
stated) — 63
Patented Market
Forecast — 64
Table: US - Patented Market Indicators,
Historical Data and Forecasts — 65
Generics Market
Forecast — 66
Table: US – Generics Market
Indicators, Historical Data And Forecasts — 67
OTC Market
Forecast — 68
Table: US – OTC Market Indicators,
Historical Data And Forecasts (US$mn unless otherwise
stated) — 69
Export/Import
Forecasts — 70
Table: US - Pharmaceuticals Trade,
Historical Data And Forecasts (US$mn) — 71
Medical Device
Market Forecasts — 72
Other Healthcare
Data — 73
Table: US – Other Healthcare Indicators,
Historical Data And Forecasts — 73
Competitive
Landscape — 74
Table: 10 Leading Corporations By Total US
Dispensed Prescriptions (mn) — 74
Table: 10 Leading
Corporations By US Sales (US$bn) — 75
Table: Leading 10
Products By US Sales (US$bn) — 75
Table: Leading 10
Products By US Dispensed Prescriptions (mn) — 76
Company
Profiles — 77
Pfizer — 77
GlaxoSmithKline (GSK) — 81
Genentech — 84
Country Snapshot: US Demographic
Data — 87
Section 1: Population — 87
Table: Demographic Indicators, 2005-2030 — 87
Table:
Rural/Urban Breakdown, 2005-2030 — 88
Section 2: Education
And Healthcare — 88
Table: Education,
2002-2005 — 88
Table: Vital Statistics,
2005-2030 — 88
Section 3: Labour Market And Spending
Power — 89
Table: Employment Indicators,
2001-2006 — 89
Table: Consumer Expenditure, 2000-2012
(US$) — 89
Table: Average Annual Wages, 2000-2012
(US$) — 90
BMI Forecast Modelling — 91
How We Generate Our Pharmaceutical Industry Forecasts — 91
Pharmaceutical Business Environment Ratings
Methodology — 92
Ratings Overview — 92
Table: Pharmaceutical Business Environment Indicators — 93
Weighting — 94
Table: Weighting Of
Components — 94
Sources — 94
| 
View Cart
